PT  - JOURNAL ARTICLE
AU  - Buckley, Rita
ED  - Perol, Maurice
TI  - Ramucirumab Improves Survival in Stage IV NSCLC
DP  - 2014 Aug 01
TA  - MD Conference Express
PG  - 14--14
VI  - 14
IP  - 14
4099  - http://mdc.sagepub.com/content/14/14/14.short
4100  - http://mdc.sagepub.com/content/14/14/14.full
AB  - Ramucirumab (IMC-1121B) is a human immunoglobulin G1 monoclonal antibody that targets the extracellular domain of vascular endothelial growth factor receptor 2. A Study of Chemotherapy and Ramucirumab versus Chemotherapy Alone in Second Line Non—Small Cell Lung Cancer Participants Who Received Prior First Line Platinum Based Chemotherapy [REVEL; NCT01168973; Garon EB et al. Lancet 2014] showed that ramucirumab combined with docetaxel extended survival in patients with advanced non—small cell lung cancer (NSCLC) compared with placebo plus docetaxel.